Grace Therapeutics
GRCE
9 hedge funds and large institutions have $704K invested in Grace Therapeutics in 2017 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 2 closing their positions.
0.03% less ownership
Funds ownership: 0.1% → 0.07% (-0.03%)
2% less capital invested
Capital invested by funds: $721K → $704K (-$17.3K)
10% less funds holding
Funds holding: 10 → 9 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$28K |
| 2 |
Renaissance Technologies
New York
|
-$4.36K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$4K |
| 4 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$307 |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$61 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PA
1
Perceptive Advisors
New York
| $254K | – | – | – |
|
2
Bank of Montreal
Toronto,
Ontario, Canada
| $238K | – | – | – |
|
|
IIM
3
Intact Investment Management
Montreal,
Quebec, Canada
| $152K | – | – | – |
|
|
4
Renaissance Technologies
New York
| $57K | -$4.36K | -71 | -8% |
|
|
FDCDDQ
5
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $2.72K | +$2.7K | +44 | New |
|
|
VKH
6
Virtu KCG Holdings
New York
| – | -$28K | -469 | Closed |
|
|
7
UBS Group
Zurich,
Switzerland
| – | -$4K | -69 | Closed |
|
|
8
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | -$307 | -5 | -83% |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| – | -$61 | -1 | -17% |
|
GRCE Hedge Fund Activity: Q1 2017 in Review
9 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q1 2017, worth a combined $704K — down 2.4% from $721K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of GRCE and 1 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 0 added.
The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $28K sold.
- 9 institutional investors held Grace Therapeutics (GRCE) as of Q1 2017, down from 10 in Q4 2016.
- Funds reported $704K of Grace Therapeutics stock for Q1 2017, down 2.4% quarter-over-quarter.
- 1 fund opened new Grace Therapeutics positions in Q1 2017 and 2 closed out, a net change of -1 holder.
- The largest Grace Therapeutics seller in Q1 2017 was Virtu KCG Holdings, an estimated $28K sold.
Based on aggregated 13F filings for Q1 2017.